person · Reporting owner

Gould Kevin S

Disclosed activity across 1 company

Tapewire entity: 172262
SEC CIK: 0001662638

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIO-TECHNE CorpTECH · Entity 3479	SVP Clinical Controls	October 26, 2017	October 30, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIO-TECHNE Corp

Report date October 26, 2017 · Filed October 30, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,949	Reported balance After 2017-10-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-10-26 · Grant · Acquired 1,949 · Balance 1,949 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,111	Reported balance Holding disclosure · report date 2017-10-26 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 2,111 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2024-08-09	Direct	10,742	Reported balance After 2017-10-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-10-26 · Grant · Acquired 10,742 · Balance 10,742 F3: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2024-08-09	Direct	14,323	Reported balance After 2017-10-26 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-10-26 · Grant · Acquired 14,323 · Balance 14,323 F4: Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021.
Common StockSEC Table I · non-derivative	Direct	1,355	Reported balance Holding disclosure · report date 2017-10-26 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,355 F1: Includes 834 shares of restricted stock units that vest on 7/9/18.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.59 · Expires 2023-08-18	Direct	17,371	Reported balance Holding disclosure · report date 2017-10-26 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 17,371 F6: Vests 4,343 shares on each of 8/18/17, 8/18/18 and 8/18/19, and 4,342 shares on 8/18/20.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.59 · Expires 2023-08-18	Direct	13,028	Reported balance Holding disclosure · report date 2017-10-26 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 13,028 F5: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.23 · Expires 2022-07-09	Direct	50,000	Reported balance Holding disclosure · report date 2017-10-26 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 50,000 F7: 50,000 common stock options vest if certain performance goals are achieved for the 12 months ending 05/31/18.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.23 · Expires 2022-07-09	Direct	15,000	Reported balance Holding disclosure · report date 2017-10-26 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance 15,000 F8: Vests as to 3,750 shares on each of 7/9/16, 7/9/17, 7/9/18 and 7/9/19.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.23 · Expires 2023-01-04	Direct	10,000	Reported balance Holding disclosure · report date 2017-10-26 · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · Balance 10,000 F9: Vests as to 2,500 shares on each of 01/04/17, 01/04/18, 01/04/19 and 01/04/20.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 834 shares of restricted stock units that vest on 7/9/18.

F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F3: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F4: Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021.

F5: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F6: Vests 4,343 shares on each of 8/18/17, 8/18/18 and 8/18/19, and 4,342 shares on 8/18/20.

F7: 50,000 common stock options vest if certain performance goals are achieved for the 12 months ending 05/31/18.

F8: Vests as to 3,750 shares on each of 7/9/16, 7/9/17, 7/9/18 and 7/9/19.

F9: Vests as to 2,500 shares on each of 01/04/17, 01/04/18, 01/04/19 and 01/04/20.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 26, 2017 Filed Oct 30, 2017 20:56 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Options (Right to buy) · Derivative	14,323	$0.00 Strike: $125.05	$0.00	Disclosure SEC source: 0001562180-17-003380 · primarydocument.xml · derivative · entry 4 Gould Kevin S · CIK 0001662638 · SVP Clinical Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,323 Underlying: Common Stock · 14,323 shares Expires 2024-08-09 F4 · derivative.exercise_date: Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021. Read SEC document
October 26, 2017 Filed Oct 30, 2017 20:56 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Options (Right to buy) · Derivative	10,742	$0.00 Strike: $125.05	$0.00	Disclosure SEC source: 0001562180-17-003380 · primarydocument.xml · derivative · entry 3 Gould Kevin S · CIK 0001662638 · SVP Clinical Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,742 Underlying: Common Stock · 10,742 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document
October 26, 2017 Filed Oct 30, 2017 20:56 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantRestricted Stock Units · Derivative	1,949	$0.00	$0.00	Disclosure SEC source: 0001562180-17-003380 · primarydocument.xml · derivative · entry 2 Gould Kevin S · CIK 0001662638 · SVP Clinical Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,949 Underlying: Common Stock · 1,949 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F3 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document
July 09, 2017 Filed Jul 11, 2017 21:30 UTC	BIO-TECHNE Corp TECH · Entity 3479	Tax withholdingCommon Stock	312	$117.68	$36,716.16	Disclosure SEC source: 0001562180-17-002466 · primarydocument.xml · nonDerivative · entry 1 Gould Kevin S · CIK 0001662638 · SVP Clinical Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,355 F1 · balance_after: Includes 834 shares of restricted stock units that vest on 7/9/18. Read SEC document
September 08, 2016 Filed Sep 12, 2016 21:27 UTC	BIO-TECHNE Corp TECH · Entity 3479	SaleCommon Stock	524	$110.50	$57,903.57	Disclosure SEC source: 0000914190-16-000832 · edgar.xml · nonDerivative · entry 1 Gould Kevin S · CIK 0001662638 · SVP Clinical Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.4934 to $110.5402 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 833 shares of restricted stock units that vest on 7/9/17 and 834 shares of restricted stock units that vest on 7/9/18. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.